TITLE 18. PROFESSIONAL AND OCCUPATIONAL LICENSING
REGISTRAR'S NOTICE: The Board
of Optometry is claiming an exemption from the Administrative Process Act in
accordance with § 2.2-4002 A 14 of the Code of Virginia, which exempts the
Board of Optometry from the Administrative Process Act when specifying
therapeutic pharmaceutical agents, treatment guidelines, and diseases and
abnormal conditions of the human eye and its adnexa for TPA-certification of
optometrists pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32 of
Title 54.1 of the Code of Virginia.
Title of Regulation: 18VAC105-20. Regulations
Governing the Practice of Optometry (amending 18VAC105-20-47).
Statutory Authority: §§ 54.1-2400 and 54.1-3223 of the
Code of Virginia.
Public Hearing Information:
October 16, 2020 - 10:35 a.m. - Department of Health
Professions, Perimeter Center, 9960 Mayland Drive, Suite 200, Board Room 4,
Henrico, VA
Agency Contact: Leslie L. Knachel, Executive Director,
Board of Optometry, 9960 Mayland Drive, Suite 300, Richmond, VA 23233,
telephone (804) 597-4130, FAX (804) 527-4471, or email leslie.knachel@dhp.virginia.gov.
Summary:
The amendment adds alpha-adrenergic agonists to the
therapeutic pharmaceutical agent formulary in the category of a topically
administered Schedule VI medication.
18VAC105-20-47. Therapeutic pharmaceutical agents.
A. A TPA-certified optometrist, acting within the scope of
his practice, may procure, administer, and prescribe medically appropriate
therapeutic pharmaceutical agents (or any therapeutically appropriate
combination thereof) to treat diseases and abnormal conditions of the human eye
and its adnexa within the following categories:
1. Oral analgesics - Schedule II controlled substances
consisting of hydrocodone in combination with acetaminophen andSchedule III,
IV, and VI narcotic and nonnarcotic agents.
2. Topically administered Schedule VI agents:
a. Alpha-adrenergic blocking agents;
b. Alpha-adrenergic agonists;
c. Anesthetic (including esters and amides);
c. d. Anti-allergy (including antihistamines and
mast cell stabilizers);
d. e. Anti-fungal;
e. f. Anti-glaucoma (including carbonic
anhydrase inhibitors and hyperosmotics);
f. g. Anti-infective (including antibiotics and
antivirals);
g. h. Anti-inflammatory;
h. i Cycloplegics and mydriatics;
i. j. Decongestants; and
j. k. Immunosuppressive agents.
3. Orally administered Schedule VI agents:
a. Aminocaproic acids (including antifibrinolytic agents);
b. Anti-allergy (including antihistamines and leukotriene
inhibitors);
c. Anti-fungal;
d. Anti-glaucoma (including carbonic anhydrase inhibitors and
hyperosmotics);
e. Anti-infective (including antibiotics and antivirals);
f. Anti-inflammatory (including steroidal and nonsteroidal);
g. Decongestants; and
h. Immunosuppressive agents.
B. Schedule I, II, and V drugs are excluded from the list of
therapeutic pharmaceutical agents with the exception of controlled substances
in Schedule II consisting of hydrocodone in combination with acetaminophen and
gabapentin in Schedule V.
C. Over-the-counter topical and oral medications for the
treatment of the eye and its adnexa may be procured for administration,
administered, prescribed, or dispensed.
VA.R. Doc. No. R21-6523; Filed September 28, 2020, 11:07 a.m.